Connect with us

Business

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S. – CNBC

“We believe that this product will never be licensed in the U.S.,” one group of critical U.S.-based analysts wrote this week.

Published

on

post featured image
ADVERTISEMENT

AstraZeneca’s building in Luton, Britain.
AstraZeneca and the University of Oxford are defending the results and methods used in their phase three vaccine trials on the back of criticism from experts in the U.S., stressing the “highest standards” were used and that “additional analysis will be conducted.” 
AstraZeneca shares are down by around 6% this week after questions were raised over its vaccine candidate, for which the company said combined results revealed it to be 70% effective. The figure…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
Live Updates: Leaked recording of Dorsey suggests Twitter policy enforcement actions will go beyond Trump ban – Fox News
post featured image
The 4 Robinhood Stocks Wall Street Hates the Most – Motley Fool
post featured image
China is set to report GDP numbers on Monday. Here’s what economists expect – CNBC